Dr. Coco Bryant brings a powerful blend of clinical insights and scientific rigor to biotech investing. Her hands-on clinical experience across diverse medical specialities including medical oncology, gastroenterology, vascular surgery and emergency medicine as an Intern and Resident Doctor at Sydney’s leading teaching hospitals, gives her a patient-centered lens for evaluating wellness-driven innovation, while her background in molecular research provides her with the technical fluency needed to assess scientific breakthroughs. Coco’s academic interests encompass precision oncology, immunology, and importantly tackling the tumor microenvironment, a critical target shaping treatment response and resistance mechanisms in oncology.

Prior to ARTIS, Coco earned top honors in biomedical research thesis at the University of New South Wales, developing CRISPR/Cas9 zebrafish Parkinson’s disease models, conducting neuronal microscopy, and engineering tissue-specific gene-editing vectors, showcasing a deep technical and experimental acumen.

During medical school Coco contributed to global health advocacy at the United Nations through Indigenous health needs assessments and media toolkits. Coco also brings a rich extracurricular profile from Australian national rowing titles to volunteering with Indigenous student mentoring, underscoring her discipline, leadership, and commitment to equity.